Compare UPLD & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UPLD | QTTB |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.4M | 44.3M |
| IPO Year | 2014 | 2018 |
| Metric | UPLD | QTTB |
|---|---|---|
| Price | $0.55 | $7.34 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $3.75 | ★ $14.00 |
| AVG Volume (30 Days) | ★ 266.9K | 171.1K |
| Earning Date | 06-03-2026 | 06-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 63.38 | ★ 136.78 |
| EPS | N/A | ★ 2.42 |
| Revenue | ★ $74,767,000.00 | $53,737,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $2.86 |
| Revenue Growth | ★ 6.95 | N/A |
| 52 Week Low | $0.51 | $1.38 |
| 52 Week High | $3.90 | $7.10 |
| Indicator | UPLD | QTTB |
|---|---|---|
| Relative Strength Index (RSI) | 13.20 | 81.68 |
| Support Level | N/A | $1.64 |
| Resistance Level | $1.62 | N/A |
| Average True Range (ATR) | 0.07 | 0.53 |
| MACD | -0.02 | 0.25 |
| Stochastic Oscillator | 8.53 | 91.95 |
Upland Software Inc is a software company. It provides cloud-based software applications in three categories: Knowledge Management that provides solutions designed to help organizations capture, organize, and distribute information to employees and customers. Content Lifecycle and Workflow Automation offers solutions that support document management, compliance, and process efficiency across various industries. Digital Marketing solutions that provides tools for audience engagement, campaign management, and content distribution across digital channels.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function.